Indian unit of Pfizer reports 3 percent rise in Q4 profit
Separately, parent Pfizer Inc reported higher-than-expected first-quarter revenue and profit, helped by demand for its COVID-19 products.
Advertisement
Bengaluru: Pfizer Ltd, the Indian unit of US pharmaceutical group Pfizer Inc, on Monday reported a 3.1 per cent rise in fourth-quarter profit, helped by lower raw material expenses.
Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2 per cent.
Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share.
WHY IT MATTERS
Pfizer's pharmaceutical segment has a portfolio of over 150 products. Separately, parent Pfizer Inc reported higher-than-expected first-quarter revenue and profit, helped by demand for its COVID-19 products.
In India, rival Cipla Ltd posted a 45.2 per cent increase in fourth-quarter profit, while Novartis India Ltd reported a quarterly profit compared with a loss a year ago.
Abbott India Ltd and GlaxoSmithKline Pharmaceuticals Ltd are scheduled to report its quarterly results later this week.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.